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AbstrAct
Extended-spectrum β-lactamase (ESBL)-producing bacteria 
causing clinical infections are often also multidrug-resistant 
(MDR; resistance to ≥3 antimicrobial drug classes), therefore 
treatment options may be limited. High carriage rates of these 
potentially zoonotic bacteria have been found in livestock and 
companion animals. Therefore, people working in veterinary 
hospitals may be a high-risk population for carriage. This is 
the first study to determine the prevalence and longitudinal 
carriage of antimicrobial-resistant (AMR) and ESBL-producing 
faecal Escherichia coli in veterinary hospital staff and 
students. Prevalence of faecal AMR and ESBL-producing E 
coli was determined in 84 staff members and students in 
three UK veterinary hospitals. Twenty-seven participants were 
followed for six weeks to investigate longitudinal carriage. 
Antimicrobial susceptibility and phenotypic ESBL production 
were determined and selected isolates were whole genome 
sequenced. ESBL-producing E coli were isolated from five 
participants (5.95 per cent; 95 per cent CI 0.89 to 11.0 
per cent); two participants carried ESBL-producing E coli 
resistant to all antimicrobials tested. Carriage of MDR E coli 
was common (32.1 per cent; 95per cent CI 22.2 to 42.1 
per cent) and there was a high prevalence of ciprofloxacin 
resistance (11.9 per cent; 95 per cent CI 4.98 to 18.8 per cent). 
ESBL-producing E coli were isolated from seven longitudinal 
participants (25.9 per cent; 95 per cent CI 9.40 to 42.5 per 
cent); two participants carried ESBL-producing E coli for the 
entire study period. Twenty-six participants (96.3 per cent; 95 
per cent CI 89.2 to 100) carried ≥1 MDR E coli isolate during 
the six-week period, with seven participants (25.9 per cent) 
carrying ≥1 MDR isolate for at least five out of six weeks. The 
prevalence of faecal ESBL-producing E coli in cross-sectional 
participants is similar to asymptomatic general populations. 
However, much higher levels of carriage were observed 
longitudinally in participants. It is vital that veterinary hospitals 
implement gold-standard biosecurity to prevent transmission 
of MDR and ESBL-producing bacteria between patients and 
staff. Healthcare providers should be made aware that people 
working in veterinary hospitals are a high-risk population for 
carriage of MDR and ESBL-producing bacteria, and that this 
poses a risk to the carrier and for transmission of resistance 
throughout the wider community.
IntroduCtIon
Extended-spectrum β-lactamase (ESBL)-pro-
ducing Enterobacteriaceae, including Escherichia 
coli, present a growing human and veteri-
nary public health risk.1 ESBLs are a family 
of bacterial enzymes, which hydrolyse the 
β-lactam ring present in β-lactam antimicro-
bials, conferring resistance to penicillins, 
second-generation to fourth-generation 
cephalosporins and monobactams. Of addi-
tional concern are AmpC-producing bacteria, 
which are also resistant to β-lactamase inhib-
itors.2 Horizontal transfer of mobile genetic 
elements encoding antimicrobial resistance 
genes in addition to ESBL or plasmid-me-
diated AmpC β-lactamase genes has led to 
common multidrug-resistant (MDR) pheno-
types.3 
The emergence of ESBL-producing and 
AmpC-producing bacteria constitute a major 
therapeutic burden, contributing to ineffec-
tive antimicrobial treatment and presenting 
economic and public health concerns to 
healthcare systems worldwide.1 4 Thus, it is 
increasingly important to identify high-risk 
populations to reduce the threat posed to 
themselves and other patients. In a study 
of UK surfers, Leonard et al5 found that 1.5 
per cent of a non-surfing, control popula-
tion were colonised by E coli-bearing blaCTX-M 
compared with 6.3 per cent of UK surfers. 
Intestinal colonisation with ESBL-producing 
bacteria before hospital admission is asso-
ciated with increased risk of nosocomial 
infection.6 Patients with infections caused 
by ESBL-producing bacteria and carriers of 
these organisms represent a source of resis-
tance and can be responsible for nosocomial 
and community transmission.7 The identifi-
cation of methicillin-resistant Staphylococcus 
aureus (MRSA) carriers and high-risk groups 
has been fundamental to successful control 
policies, such as The Netherlands’ ‘Search 
and Destroy’ policy.8 Similar strategies, 
including decolonisation regimes, have been 
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proposed for the control of ESBL-producing bacteria in 
human hospital environments.6
Multiple studies have identified antimicrobial-resistant 
(AMR) faecal E coli in small animals,9–11 livestock12–14 
and equids,15–18 presenting a direct risk of colonisation 
to those working with these species, including veterinar-
ians.19 However, there is a lack of published estimates 
of faecal carriage of AMR and ESBL-producing E coli by 
people working in veterinary environments. It is well-doc-
umented that carriage of MRSA by veterinarians, pet 
owners and people occupationally exposed to animals is 
substantially higher than in healthy, non-veterinary popu-
lations, including in the UK.20 Thus, it can be hypoth-
esised that carriage of other types of AMR bacteria will 
be higher among those in veterinary roles and that these 
individuals provide a reservoir of virulence and resistance 
genes for transmission throughout other human and 
animal populations.
This study aimed to investigate the prevalence of faecal 
carriage of AMR and ESBL-producing E coli by staff and 
students working in three UK veterinary hospitals. Using 
questionnaires, potential risk factors for faecal carriage 
of these bacteria were assessed. In addition, a subpopula-
tion of individuals was recruited for a longitudinal study 
to investigate the length of human faecal carriage of 
AMR and ESBL-producing E coli.
Methods
study population and sampling protocol
Veterinary staff and students were recruited from one 
equine referral teaching hospital (EH), one small animal 
referral teaching hospital (SAH) and one farm animal 
first-opinion and referral teaching hospital (FAH) on the 
same campus between February and June 2015. Partici-
pants were recruited by convenience sampling; the study 
was advertised to potential participants with posters in 
each hospital, through email and by word-of-mouth. All 
participants were aged over 16 years and there were no 
exclusion criteria.
The prevalence of ESBL-producing bacteria in this 
healthy human population was estimated to be similar to 
estimates of other European healthy human populations, 
approximately 5 per cent. A sample size calculation was 
performed using the online EpiTools epidemiological 
calculators21 to determine prevalence. From approxi-
mately 186 members of staff in the SAH, 61 in the EH, 
30 in the FAH and 278 clinical veterinary students, the 
total number of staff and students within the three hospi-
tals was calculated to be approximately 555. Thus, with 
an expected prevalence of 5 per cent, precision of 5 per 
cent and confidence level of 95 per cent, 65 people were 
required to provide faecal swabs.
Cross-sectional study participants could take part anon-
ymously; provision of a faecal swab and a completed 
four-page questionnaire regarding potential risk factors 
for carriage of AMR and ESBL-producing bacteria was 
considered informed consent (online supplementary 
material). Participants were asked to provide an email 
address if they were interested in participating in a longi-
tudinal study where they would be required to provide 
one faecal swab once a week for a six-week period 
between May–July 2015. Longitudinal study participants 
were asked if they had taken antimicrobials, if they or a 
member of their household had been hospitalised or if 
they had travelled abroad following participation in the 
cross-sectional and/or during participation in the longi-
tudinal study. 
Bacterial isolation
Briefly, participants were provided with a sterile cotton 
swab to collect a small amount of freshly voided faeces. A 
faecal homogenate was prepared in 1 ml brain-heart-in-
fusion broth with 5 per cent glycerol. Also, 500 µl of 
homogenate was enriched in 4.5 ml buffered peptone 
water and incubated aerobically at 37°C for 18–24 hours 
before culture on three eosin methylene blue agar 
(EMBA) plates (one plain, one with 1 µg/ml cefotaxime 
and one with 1 µg/ml ceftazidime). An additional 
EMBA plate was inoculated with faecal homogenate for 
confluent bacterial growth and four antimicrobial discs 
were applied: 10 µg ampicillin, 30 µg amoxicillin-clavu-
lanate, 1 µg ciprofloxacin and 2.5 µg trimethoprim, as 
previously described.11 22 Following aerobic incubation at 
37°C for 18–24 hours, three colonies, whose morphology 
resembled E coli, were selected from plain EMBA. One 
colony growing on each of the cefotaxime and ceftazi-
dime plates and within the zone of inhibition around 
each antimicrobial disc was selected if present. Thus, up 
to nine colonies were selected per sample. Antimicro-
bial discs were obtained from Mast Group (Bootle, UK), 
media from LabM (Bury, UK) and antibiotic powder 
from Sigma-Aldrich (Dorset, UK).
Antimicrobial susceptibility testing
Antimicrobial susceptibility disc diffusion testing was 
performed according to British Society for Antimicro-
bial Chemotherapy guidelines23 on up to nine colonies 
per sample. Seven antimicrobial discs were applied to 
susceptibility plates: 10 µg ampicillin, 30 µg amoxicil-
lin-clavulanate, 30 µg chloramphenicol, 30 µg nalidixic 
acid, 1 µg ciprofloxacin, 2.5 µg trimethoprim and 30 µg 
tetracycline. Plates were incubated aerobically at 37°C for 
18–24 hours.
Phenotypic identification of esBL-producing bacteria
The double disc diffusion test for ESBL production was 
performed on isolates selected from cephalosporin-con-
taining EMBA plates, as previously described.11 ESBL 
production was confirmed when the zone around the 
cephalosporin disc was expanded in the presence of the 
clavulanic acid by a minimum of 5 mm for at least one 
antimicrobial pair. The AmpC phenotype was suggested 
when the inhibition zone did not increase with the pres-
ence of clavulanic acid, but resistance to at least one 
cephalosporin was evident.
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Genotypic identification of E coli and characterisation of 
resistance genes by PCr
PCR assays for the uidA gene confirmed isolates as E 
coli.24 All isolates selected from cephalosporin-containing 
EMBA plates were tested for the presence of predomi-
nant ESBL gene variants (blaCTX-M
25 (groups 1,26 227 and 
9),28 blaTEM, blaSHV and blaOXA
29). A family-specific multi-
plex PCR for plasmid-mediated AmpC β-lactamase genes 
(blaAmpC) was performed on all isolates selected from 
cephalosporin-containing EMBA plates and isolates 
displaying resistance to amoxicillin-clavulanate.30
Whole-genome sequencing (WGs)
Fifty-three E coli isolates were selected for WGS; isolates 
were selected either due to detection of blaCTX-M, blaTEM, 
blaSHV, blaOXA or blaAmpC genes by PCR, or for further charac-
terisation of AMR or MDR resistance profiles. Briefly, DNA 
was extracted from overnight cultures of selected isolates 
using the QIAamp DNA Mini Kit (Qiagen, Manchester, 
UK). DNA was then quantified and assessed for purity 
using a Nanodrop spectrophotometer (ThermoFisher 
Scientific, Cheshire, UK) before being forwarded to the 
University of Swansea for WGS. Sequence libraries were 
prepared using the Nextera XT v2 library preparation kit 
and sequenced on a MiSeq desktop sequencer (Illumina, 
San Diego, USA) using MiSeq V3 reagent kits. Genome 
assemblies of the 300 bp short read pair end data was 
undertaken using the de novo assembly algorithm SPAdes 
V.3.3.31 Genomes and short read data are archived on the 
NCBI GenBank and SRA depositories, associated with 
BioProject PRJNA454281 (https://www. ncbi. nlm. nih. 
gov/ bioproject/ PRJNA454281). Individual accession 
numbers, complete details of the number of contigs and 
assembled genome size for each of the sequenced isolates 
are available in online supplementary material. A refer-
ence pan-genome approach32 with gene-by-gene align-
ment33 34 was implemented using the open source Bacte-
rial Isolate Genome Sequence Database: BIGSdb,35 which 
includes functionality to call MLST profiles defined by the 
PubMLST database (http:// bigsdb. pasteur. fr/ ecoli/). 
MLST types for each isolate were corroborated using the 
online tool MLST V.1.836 MAFFT software37 was used to 
align gene orthologs and concatenated into contiguous 
sequence for each isolate genome including gaps. Based 
on the K12 reference genome (accession: NC_000913.3; 
4319 loci) a core genome alignment (genes present in 90 
per cent or more isolates) was constructed (3,344,351 bp; 
3473 loci) and a heuristic maximum-likelihood tree 
generated using FastTree2 (V.2.1.0).38 Core genome 
genealogies and meta-data were visualised using Micro-
react39 and shared: https:// microreact. org/ project/ 
RoydenVetEcoli.
The online tools ResFinder V.3.040 and VirulenceFinder 
V.1.541 were used to determine carriage of antimicrobial 
resistance genes and virulence genes. PlasmidFinder 
V.1.342 was used to assess for the presence of plasmid repl-
icons and pMLST V.1.442 and the plasmid MLST website 
(https:// pubmlst. org/ plasmid/)35 allocated Inc replicon 
sequence types (RSTs) for isolates where PlasmidFinder 
identified one or more incompatibility groups for which 
schemes are available (IncF, IncHI1, IncHI2, IncN and 
IncI1). In silico serotyping of isolates was undertaken 
using SerotypeFinder V.1.143 in order to assess the O and 
H serogroups of each isolate.
Statistical analysis
Twenty-four independent, binomial and categorical 
predictor variables were created from 84 cross-sectional 
study participant questionnaires. Outcome data for AMR 
E coli were collapsed to the sample level. Therefore, 
a sample with at least one resistant faecal E coli isolate 
was classed as resistant for analysis. Fourteen binomial 
antimicrobial resistance outcomes were considered as 
response variables: (i) ampicillin resistance, (ii) amox-
icillin-clavulanate resistance, (iii) nalidixic acid resist-
ance, (iv) ciprofloxacin resistance, (v) chloramphenicol 
resistance, (vi) trimethoprim resistance, (vii) tetracy-
cline resistance (viii) β-lactam resistance (ix) quinolone 
resistance, (x) third-generation cephalosporin resist-
ance, (xi) resistance to ≥1 tested antimicrobial, (xii) 
MDR=resistance to≥3 tested antimicrobials, (xiii) resist-
ance to all five tested antimicrobial classes (β-lactams, 
quinolones, chloramphenicol, trimethoprim and tetra-
cycline) and (xiv) sample containing ESBL-producing E 
coli. Univariable logistic regression models analysed the 
association between all independent predictor variables 
and resistance outcomes (online supplementary mate-
rial). Variables were tested in multivariable models if the 
likelihood-ratio test P value<0.25. Collinearity between 
explanatory variables was assessed using Pearson’s 
chi-square test for independence, or if n<5, Fisher’s exact 
test. For variables with a significant association (P<0.05) 
only variables with the lowest P value were considered for 
inclusion in the multivariable models. Final models were 
constructed by manual backwards stepwise procedures 
where variables with a likelihood-ratio test P-value<0.05 
were retained. The fit of the model was then tested using 
graphical residual analysis.
Pearson’s chi-square test for independence, or if n<5, 
Fisher’s exact test, was performed to determine any statis-
tically significant differences in AMR data between the 
three veterinary teaching hospitals. All statistical tests 
were performed using R (R V.3.2.0 for Mac OS X).44
resuLts
Cross-sectional study
Study population
From a population of approximately 555 potential study 
participants, a total of 84 participants were recruited, and 
their occupations and workplaces are shown in table 1.
Phenotypic antimicrobial resistance
E coli were isolated from 78 samples (92.9 per cent; 95 per 
cent CI: 87.3 to 98.4 per cent). Of these, 27 (32.1 per cent; 
95 per cent CI 22.2 to 42.1 per cent) samples contained 
at least one MDR (resistance to ≥3 antimicrobial drug 
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classes) E coli and 6 (7.14 per cent; 95 per cent CI 1.64 
to 12.7 per cent) contained at least one E coli isolate 
resistant to all five antimicrobial classes tested. There 
was a notably high prevalence of resistance to ciproflox-
acin (11.9 per cent; 95 per cent CI 4.98 to 18.8 per cent). 
The percentage of samples containing at least one E 
coli isolate resistant to each of the tested antimicrobials 
is shown in table 2. ESBL-producing E coli were isolated 
from five samples (5.95 per cent: 95 per cent CI 0.89 
to 11.0 per cent); two of these samples (E38 and S57) 
contained MDR ESBL-producing E coli, resistant to all 
antimicrobials tested (table 3). Comparisons between the 
three hospitals revealed a significantly higher prevalence 
of trimethoprim-resistant E coli in the FAH compared 
with the SAH (Χ2=7.09, P=0.008).
A total of 151 unique E coli isolates were identified from 
the antimicrobial resistance profiles of all E coli isolates 
from 84 samples (online supplementary material). From 
a large diversity of resistance profiles, the most common 
resistance profile was to ampicillin, followed by ampi-
cillin-trimethoprim-tetracycline. Nineteen participants 
were found to be carrying more than one unique E coli 
isolate with different AMR profiles.
Characterisation of resistance genes and WGS
In total, 29 unique E coli isolates from 25 cross-sectional 
study participants were selected for WGS either due 
to detection of blaCTX-M, blaTEM, blaSHV, blaOXA or blaAmpC 
genes by PCR, or for further characterisation of their 
AMR or MDR resistance profiles (table 3). Examination 
of isolates from the five samples carrying phenotypic 
ESBL-producing E coli revealed blaCTX-M-15 in four isolates, 
and blaCTX-M-14 and blaCTX-M-27 individually in two isolates. 
Through WGS, three additional E coli isolates were 
confirmed as putative ESBL producers, carrying blaTEM-33 
or blaSHV-40 genes, and three isolates were revealed to carry 
blaCMY-2.
Examination of the 29 isolates revealed genes confer-
ring resistance to ten antimicrobial classes; the most 
common being the aminoglycoside resistance genes, 
strA (n=11) and strB (n=15), the sulphonamide resis-
tance genes, sul1 (n=11) and sul2 (n=13), and the tetra-
cycline resistance gene, tet(A) (n=10). Aside from the 10 
bla genes identified, of which 6 encode ESBL or AmpC 
enzymes, 36 other resistance genes were recognised; 
Table 2 The percentage of samples from 84 participants (95% CI; N) containing at least one faecal E coli isolate resistant to 
the tested antimicrobials; overall and stratified by hospital
Resistance All participants FAH EH SAH
AMP 53.6 (42.9 to 64.2; 45) 56.3 (39.1 to 73.4; 18) 55.0 (33.2 to 76.8; 11) 50.0 (32.7 to 67.3; 16)
AMC 10.7 (4.10 to 17.3; 9) 15.6 (3.04 to 28.2; 5) 5.0 (0 to 14.6; 1) 9.38 (0 to 19.5; 3)
NAL 25.0 (15.7 to 34.3; 21) 28.1 (12.5 to 43.7; 9) 25.0 (6.02 to 44.0; 5) 21.9 (7.55 to 36.2; 7)
CIP 11.9 (4.98 to 18.8; 10) 15.6 (3.04 to 28.2; 5) 10.0 (0 to 23.1; 2) 9.38 (0 to 19.5; 3)
CHL 16.7 (8.70 to 24.6; 14) 15.6 (3.04 to 28.2; 5) 20.0 (2.47 to 37.5; 4) 15.6 (3.04 to 28.2; 5)
TMP 34.5 (24.4 to 44.7; 29) 50.0 (32.7 to 67.3; 16) 40.0 (18.5 to 61.5; 8) 15.6 (3.04 to 28.2; 5)
TET 39.3 (28.8 to 49.7; 33) 46.9 (29.6 to 64.2; 15) 40.0 (18.5 to 61.5; 8) 31.3 (15.2 to 47.3; 10)
BLM 53.6 (42.9 to 64.2; 45) 56.3 (39.1 to 73.4, 18) 55.0 (33.2 to 76.8; 11) 50 (32.7 to 67.3; 16)
QNL 25.0 (15.7 to 34.3; 21) 28.1 (12.5 to 43.7; 9) 25.0 (6.02 to 44.0; 5) 21.9 (7.55 to 36.2; 7)
3GCR 10.7 (4.10 to 17.3; 9) 9.38 (0 to 19.5; 3) 5.0 (0 to 14.6; 1) 15.6 (3.04 to 28.2; 5)
AMR 60.7 (50.3 to 71.2, 51) 59.4 (42.4 to 76.4; 19) 65.0 (44.1 to 85.9; 13) 59.4 (42.4 to 76.4; 19)
MDR 32.1 (22.2 to 42.1; 27) 40.6 (23.6 to 57.6, 13) 35.0 (14.1 to 55.9; 7) 21.9 (7.55 to 36.2; 7)
ALL 7.14 (1.64 to 12.7; 6) 12.5 (1.04 to 24.0; 4) 5.0 (0 to 14.6; 1) 3.13 (0 to 9.15; 1)
ESBL 5.95 (0.892 to 11.0; 5) 3.13 (0 to 9.15; 1) 5.0 (0 to 14.6; 1) 9.38 (0 to 19.5; 3)
ALL, resistance to all five tested antimicrobial classes (β-lactams, quinolones, chloramphenicol, trimethoprim and 
tetracycline); AMC, amoxicillin clavulanate resistance; AMP, ampicillin resistance; AMR, resistance to≥1 tested antimicrobial; 
BLM, β-lactam resistance; CHL, chloramphenicol resistance; CIP, ciprofloxacin resistance; EH, equine hospital; ESBL, sample 
contained ESBL-producing E coli.; FAH, farm animal hospital; MDR, resistance to≥3 tested antimicrobials; NAL, nalidixic acid 
resistance; QNL, quinolone resistance; SAH, small animal hospital; TET, tetracycline resistance; TMP, trimethoprim resistance; 
3GCR, third-generation cephalosporin resistance
Table 1 Occupations and workplaces of 84 cross-sectional 
study participants
FAH EH SAH Total
Veterinary surgeon 13 13 23 49
Veterinary nurse 0 2 3 5
Veterinary student 15 5 4 24
Auxiliary staff 2 0 1 3
Administrative or other role 2 0 1 3
Total 32 20 32 84
EH, equine hospital; FAH, farm animal hospital; SAH, small animal 
hospital.
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of which 17 were only identified once. Specific exam-
ination of further resistance genes carried by the 12 
isolates harbouring the six plasmid-mediated bla genes 
encoding ESBL or AmpC enzymes identified 21 other 
class-specific resistance genes, with individual isolates 
carrying up to 11 resistance genes in addition to any 
bla genes. As can be seen in table 3, WGS highlighted 
the presence of resistance genes for which the isolates 
demonstrated phenotypic resistance on antimicrobial 
susceptibility testing.
In silico plasmid replicon typing revealed plas-
mids belonging to 10 replicon groups, with all isolates 
carrying at least 1 replicon type and one isolate 6 repl-
icon types. Eighteen different IncF RSTs were identified. 
Two isolates (73 and 229) were identified as carrying 
the same plasmid replicon type IncF RST F40:A-:B- and 
both carried blaTEM-1B, strA, strB, sull2, tet(A), gad and iss 
genes. Additionally, Isolates 299 and 331, isolated from 
two participants working in the SAH, were both carrying 
a IncF RST F29:A-:B10 plasmid and both carried the 
gad and senB (plasmid-encoded enterotoxin tieB) genes. 
From the 11 isolates harbouring an IncI1 replicon, 5 
IncI1 groups were identified. In silico serotyping desig-
nated 21 isolates an O serogroup and all 29 isolates a H 
serogroup. In total, 12 O antigens and 14 H antigens were 
identified.
WGS revealed a range of 19 different MLST types in 
the 29 isolates; 15 STs were specific to one participant 
and 4 STs (ST10, ST69, ST141 and ST405) occurred in 
more than one participant. The 14 isolates confirmed 
as carrying bla genes encoding ESBL or AmpC enzymes 
belonged to eight different STs. ST405 was identified in 
two participants carrying MDR phenotypic ESBL-pro-
ducing isolates with the blaCTX-M-15 gene. The heuristic 
maximum-likelihood phylogenetic tree of 53 isolates 
(figure 1) indicates that there is very little relationship 
between the workplace of the participant the isolate 
was collected from and the isolates’ relatedness. The 
ESBL-producing isolates from different participants were 
not clustered closely together. Further visualisation of the 
core genome genealogies with extensive isolate metadata 
is available using Microreact39 at https:// microreact. 
org/ project/ RoydenVetEcoli.
Risk factors for carriage of AMR E coli
Univariable logistic regression analysis is available in 
online supplementary material. One significant multi-
variable logistic regression model was constructed; work-
place, direct contact with animal faeces at work and 
hospitalisation in the last six months were independently 
associated with carriage of trimethoprim-resistant E coli 
(P<0.001) (table 4).
Longitudinal study
Twenty-seven cross-sectional study participants were 
recruited for the longitudinal study; 24 veterinary 
surgeons, 1 veterinary student, 1 veterinary nurse and 1 
auxiliary staff member. Eleven longitudinal participants Is
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were from the FAH, eight from the EH, seven from the 
SAH and one veterinary student on hospital rotations.
Twenty-six participants (96.3 per cent; 95 per cent CI 
89.2 to 100 per cent) were found to carry at least one 
MDR faecal E coli during the six-week period, with 16 
participants (59.3 per cent) carrying at least one AMR 
E coli isolate and 7 participants (25.9 per cent) carrying 
at least one MDR E coli isolate for at least five out of six 
weeks (figure 2). Phenotypic ESBL-producing E coli were 
isolated from seven participants (25.9 per cent; 95 per 
cent CI 9.40 to 42.5 per cent) during the study period; 
with three participants (F03, S25 and S59) demonstrating 
persistent carriage in at least five out of six samples. 
Further characterisation by PCR and WGS revealed 
weekly similarities and variations in strains and resistance 
phenotypes between isolates from these three partici-
pants (table 5).
Sixteen participants were found to be carrying resis-
tance genes (blaCTX-M, blaTEM, blaSHV, blaOXA and/or blaAmpC) 
tested for by PCR assay. PCR detected blaAmpC genes in 
isolates from seven participants; four participants carried 
blaCIT and three blaACC. The same resistance genes were 
detected in multiple samples from six participants; three 
participants (F03, S25 and S59) were found to be carrying 
the same resistance genes by PCR assay for multiple weeks 
and had multiple isolates further characterised by WGS 
(table 5).
dIsCussIon
The prevalence of ESBL-producing E coli in people 
working in three veterinary hospitals in the UK was esti-
mated to be 5.95 per cent (95 per cent CI 0.89 to 11.0 
per cent). It was hypothesised that a higher carriage rate 
Figure 1 Heuristic maximum-likelihood tree of 53 isolates generated using FastTree2 (V.2.1.0).38 Core genome genealogies 
and meta-data were visualised using Microreact.39 Further visualisation with extensive isolate metadata is available at 
https://microreact.org/project/RoydenVetEcoli. Taxa are labelled with isolate number. Colour of node represents workplace 
of participant isolate was isolated from: yellow = equine hospital, blue = farm animal hospital, red = small animal hospital. 
Metadata represents MLST type (Achtman) of isolates. The scale bar (0.013) indicates the number of substitutions per site
Table 4 Final multivariable logistic regression model for carriage of trimethoprim-resistant (Tmp-R) E coli in 84 cross-
sectional study participants
Resistance 
outcome Covariates
Tmp-R
positive
(n=29)
Tmp-R
negative
(n=55) B SE (b)
Adjusted 
OR 95% CI P value*
Trimethoprim-
resistance
(P=0.00109†)
Farm animal hospital (reference 
category)
16 16 − − − − 0.00324
Equine hospital 8 12 −0.29 0.62 0.75 0.22 to 2.51 0.639
Small animal hospital 5 27 −2.13 0.74 0.12 0.02 to 0.45 0.00389
Direct contact with animal faeces 
at work
24 51 −2.19 0.99 0.11 0.01 to 0.72 0.0208
Hospitalisation in the last six 
months
4 1 2.30 1.26 9.97 1.14 to 235.15 0.0371
If not specified, the reference category is the absence of the risk factor.
*P value from Wald test.
†P value from likelihood-ratio test statistic. 
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would be found in this population than in the general 
population due to contact with domestic animals and 
antimicrobial use in the veterinary hospital environ-
ment. Previous prevalence estimates of asymptomatic 
control populations in the UK are 1.5 and 7.3 per cent.5 45 
However, the latter study sampled individuals from an 
ethnically diverse population.45 Such populations may 
travel internationally to areas with high prevalence of 
ESBL-producing bacteria, a known risk factor for such 
carriage.46 47 Other recent European studies of healthy 
asymptomatic volunteers have found prevalence rates 
varying from 2.3 to 5.8 per cent.48–51 Dolejska et al15 found 
one (1/12) rectal swab from equine veterinary clinic staff 
positive for ESBL-producing E coli in the Czech Republic. 
This study identified one positive faecal swab from the 
EH (n=20), one from the FAH (n=32) and three from the 
SAH (n=32). Of the five samples from the cross-sectional 
study containing ESBL-producing E coli, the three carrying 
blaCTX-M-15 were collected from participants working in 
each hospital, and the two samples carrying blaCTX-M-14 and 
blaCTX-M-27 were isolated from participants from the SAH. 
Interestingly, blaCTX-M-14 is commonly associated with live-
stock, yet was isolated from a participant in the SAH.52 
Isolates from two of the participants carrying blaCTX-M-15 
were identified as ST405, which is globally associated with 
CTX-M-15.53 Isolate 350, belonging to serotype O25:H4 
and ST131, was found to carry blaCTX-M-27, which is increas-
ingly associated with the human pandemic E coli clone 
O25:H4-ST131.54
High prevalences of AMR (60.7 per cent; 95 per cent 
CI 50.3 to 71.2 per cent), MDR (32.1 per cent; 95 per 
cent CI 22.2 to 42.1 per cent) and ciprofloxacin-resistant 
(11.9 per cent; 95 per cent CI 4.98 to 18.8 per cent) E 
coli were found in cross-sectional study participants. The 
Figure 2 Timeline of results for 27 longitudinal study participants. Each row of six capsules represents the faecal carriage 
results of one participant. The black capsule at the start of each row is the participant’s ID number. The letter in front of 
each participant’s ID number indicates workplace (E=equine hospital, S=small animal hospital, F=farm animal hospital, 
U=undergraduate veterinary student). Each capsule of two halves represents the results for one week: the left side represents 
isolation by culture of antimicrobial-resistant (AMR) E coli, with the number of antimicrobial classes E coli in the sample 
demonstrated resistance to, the right side represents identification of Extended-spectrum β-lactamase (ESBL)-producing E coli 
and ST from whole genome sequencing (WGS) if available. Grey/blank capsules indicate no E coli isolated from that week’s 
sample.
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fluoroquinolone ciprofloxacin is designated a highest-pri-
ority critically important antimicrobial, which should not 
be used as a first-line treatment in people and animals,1 
therefore this high prevalence of ciprofloxacin resistance 
was unexpected. It is well known that people occupa-
tionally exposed to animals have higher rates of carriage 
of MRSA than the general population.20 Additionally, 
studies investigating the carriage of AMR and ESBL-pro-
ducing bacteria by people working with animals have 
found higher carriage rates in farmers than the general 
population.12–14 55 Notably, Huijbers et al14 55 reported the 
prevalence of ESBL-producing and AmpC-producing 
E coli in broiler farmers to be 19.1 per cent compared 
with 5.1 per cent in the local surrounding non-farming 
community.
High rates of carriage of AMR and ESBL-producing 
bacteria have also been found in the populations of 
hospitalised domestic species in the hospitals investigated 
in this study. In the SAH, 31.6 per cent of hospitalised 
cats and dogs were found to be carrying MDR bacteria 
and 26.5 per cent carried ESBL-producing bacteria.10 
Maddox et al17 found 47.7 per cent of samples from 
horses hospitalised in the EH carried MDR E coli and 
53.4 per cent carried ESBL-producing E coli. Following 
hospitalisation, equine faecal E coli AMR profiles signifi-
cantly altered and carriage of AMR and MDR E coli was 
significantly higher. Within the hospital environment, 
patients’ commensal flora are exposed to greater selec-
tion pressures for AMR than when the patient is in the 
community. These selection pressures are influenced by 
the widespread use of antimicrobials and disinfectants 
and co-habitation with other patients being treated with 
antimicrobials or carrying AMR bacteria.16 17 The high 
levels of carriage of AMR E coli in the human and animal 
populations within the study hospitals may be due to 
transmission from hospitalised animals or the hospital 
environment, acquisition of resistance determinants 
from other bacteria from these sources or from the indi-
vidual’s gut flora, or an increase in resistant E coli already 
present in the gastrointestinal flora.17
This study is the first to longitudinally study the faecal 
carriage of AMR and ESBL-producing E coli by people 
working in veterinary hospitals. Interestingly, longitu-
dinal sampling revealed that a much higher percentage 
of participants (7/27; 25.9 per cent (95 per cent CI 9.40 to 
42.5 per cent)) carried ESBL-producing E coli at least once 
during a six-week study period than during cross-sectional 
sampling, with persistent carriage of ESBL-producing E 
coli in at least five out of six samples from three partici-
pants. Zurfluh et al56 demonstrated persistent carriage in 
an international traveller to India of <8 months duration. 
Moreover, two longitudinal Swedish studies have investi-
gated carriage of ESBL-producing E coli by international 
travellers and both detected persistent colonisation of 
participants of up to three years duration.46 47 Tham 
et al47 demonstrated that ESBL-producing E coli strains 
isolated from some patients changed over the course 
of the longitudinal study. In this study, ESBL-producing P
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isolates with identical resistance profiles with the same 
resistance genes and MLST type were isolated from 
consecutive weekly samples. However, ESBL-producing 
E coli isolates were found with diverse resistance profiles 
and varying resistance genes from individual samples 
and participants and ESBL-producing isolates with the 
same MLST type were isolated from individual partici-
pants in non-consecutive weeks. These findings could be 
explained by the transfer of resistance genes, for example, 
by plasmid transfer, from a colonising E coli strain to the 
resident commensal E coli in the participant’s gut flora. 
It is possible that transmission of resistance genes and/
or isolates is occurring between the human and animal 
populations within these hospitals. Transmission events 
have been previously demonstrated in veterinary envi-
ronments between people and animals15 19 and future 
studies should aim to concurrently sample the hospital 
patients, staff and environment to investigate transmis-
sion. It is also possible that, during the study, participants 
were colonised by multiple ESBL-producing E coli, but not 
all were cultured from each sample due to variations in 
faecal shedding or limitations in microbiological culture. 
Additionally, participants may have become colonised 
with a different ESBL-producing E coli during the study. 
Ultimately, this study has shown that people working in 
veterinary environments may carry ESBL-producing E 
coli transiently for a single week or more persistently over 
multiple weeks. To enable comparisons, further work 
should include community-based longitudinal cohort 
studies.
Multivariable logistic regression analysis revealed that 
workplace, direct contact with animal faeces at work and 
hospitalisation in the last six months were independently 
associated with carriage of trimethoprim-resistance E coli 
(P<0.001). Previous studies have identified recent antimi-
crobial treatment and hospitalisation,57 and contact with 
domestic animals,58 horses55 and broiler chickens14 59 as 
risk factors for carriage of AMR and ESBL-producing 
Enterobacteriaceae. However, regression analyses could not 
construct any other significant (P<0.05) multivariable 
models for other resistance outcomes. It was difficult 
to draw statistically valid conclusions from many of the 
univariable and multivariable logistic regression models 
due to difficulties with participant recruitment. This 
resulted in similarity in some questionnaire responses and 
a low observed prevalence of some resistance outcomes.
While the use of convenience sampling to select 
participating hospitals and study participants may have 
introduced some bias, it is unlikely that this would affect 
the observed prevalence of faecal carriage of AMR or 
ESBL-producing E coli. Poor compliance for faecal sample 
submission for health screening and research studies is 
well documented worldwide.5 Reasons cited for non-sub-
mission often include procrastination, inconvenience 
and perceived unpleasantness of collecting a faecal 
sample. To improve compliance in this study, partici-
pants were asked to provide a swab of faeces as opposed 
to a whole faecal sample. Advertisement of the study was 
frequent and ubiquitous and sample packs were conve-
niently located to increase participation. Despite this, 
participant recruitment was a difficult process. Moreover, 
both cross-sectional and longitudinal study participants 
were overwhelmingly qualified veterinary surgeons. 
This may be because the study hospitals are teaching 
and referral hospitals where veterinary surgeons are 
likely to be involved in veterinary research. Thus, these 
individuals may be more motivated to participate in 
research studies, despite having to provide a faecal swab, 
than those members of staff and students not actively 
involved in research. Sampling techniques other than 
convenience sampling would not have been effective in 
this study due to the reluctance of the study population 
to provide faecal swabs for analysis. While the required 
sample size of 65 was achieved in this study, more work 
needs to be done to improve the perception of human 
faecal sampling to ensure that research studies not able 
to offer compensation in return for sampling achieve 
sufficient sample sizes.
In conclusion, this study is the first to estimate the prev-
alence of ESBL-producing E coli in people working in 
three veterinary hospitals in the UK (5.95 per cent; 95 per 
cent CI 0.89 to 11.0 per cent). It is the first longitudinal 
study of faecal carriage of AMR and ESBL-producing E 
coli by people working in veterinary hospitals and found 
that 25.9 per cent of longitudinal participants provided 
at least one ESBL-producing E coli-positive sample during 
the six-week study period. This study demonstrates that 
people working in veterinary environments are carriers 
of ESBL-producing E coli and may act as a reservoir of 
ESBL-producing bacteria in the community. Prior intes-
tinal colonisation with ESBL-producing bacteria is a 
risk factor for nosocomial infection and carriers may 
be a source of ESBL-producing bacteria in the popula-
tion.6 7 This has serious implications for carriers them-
selves, their families and their communities. It is vital that 
veterinary hospitals implement gold-standard biosecurity 
to prevent transmission of MDR and ESBL-producing 
bacteria between patients and staff. Healthcare providers 
should be made aware that people working in veterinary 
hospitals are a high-risk population for carriage of MDR 
and ESBL-producing bacteria and that this poses a risk to 
the carrier and for transmission of resistance throughout 
the wider community.
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